Delaying Diabetes Progression After Impaired Glucose Improves Long-Term Outcomes
By Lori Solomon HealthDay Reporter
WEDNESDAY, July 10, 2024 -- Maintaining several years of nondiabetes status after impaired glucose tolerance (IGT) diagnosis is associated with a significantly lower risk for poor long-term outcomes, according to a study published online July 9 in PLOS Medicine.
Xin Qian, from the Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing, and colleagues examined the association between years of nondiabetes status after diagnosis of IGT and the risk for long-term death and cardiovascular outcomes. The analysis included 540 individuals with IGT participating in the original Da Qing Diabetes Prevention Study who either maintained nondiabetes status or progressed to diabetes at the end of two, four, or six years after diagnosis of IGT.
The researchers found that the difference in the cumulative incidence rate of the outcomes between the diabetes and nondiabetes groups gradually increased over 30 years. There was a significantly lower risk for all-cause death (hazard ratio [HR], 0.74), cardiovascular events (HR, 0.63), and microvascular complications (HR, 0.62) observed in individuals who maintained nondiabetes status at the four-year visit compared with the diabetes group. A significant risk reduction in cardiovascular death was first seen at the end of six years (HR, 0.56), when adjusting for age, sex, smoking status, body mass index, systolic blood pressure, blood glucose, total cholesterol, intervention, and medications (including insulin plus oral hypoglycemics, antihypertensives, and lipid-lowering agents).
"The implementation of effective interventions targeting those with IGT should be considered as part of preventative management for diabetes and diabetes-related vascular complications," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists
WEDNESDAY, April 30, 2025 -- Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2...
Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
WEDNESDAY, April 30, 2025 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study...
Metabolic Syndrome Linked to Increased Risk for Young-Onset Dementia
THURSDAY, April 24, 2025 -- Metabolic syndrome (MetS) and its individual components are associated with an increased risk for young-onset dementia (YOD), according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.